At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
Panobinostat +2 moredrug
Likely dose
Panobinostat 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study of MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating Panobinostat, Dexamethasone, and 1 other intervention for Multiple Myeloma and 3 related conditions. Completed, enrolled 16 participants across 2 sites.
Detailed Summary
This study will look at the safety and tolerability of the new drug MLN9708 in combination with the existing drugs panobinostat and dexamethasone among patients with relapsed or refractory multiple myeloma. This study will also look at the response and clinical benefit of the treatment and the progression-free survival and overall survival of study participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma, Kahler Disease, Plasma-Cell Myeloma, Myelomatosis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 2014
Enrollment StartMay 2014
Primary CompletionMay 2018
TodayJul 2026
First PostedFeb 7, 2014
Enrollment StartMay 22, 2014
Primary CompletionMay 15, 2018
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 12.4 years ago
Interventions
Panobinostatdrug
20mg, on day 1, 3, 5, 15, 17, 19, 28
Dexamethasonedrug
20mg, on day 1, 2, 8, 9, 15, 16, 28
MLN9708drug
4mg on day 1, 8, 15, 28